Tuesday, November 26, 2019



AFTER  A LONG  PERIOD OF  CONSOLIDATION MID CAP PHARMA SECTOR SEEMS A TO  BE  RECOVERY  MODE. IAM  BULLISH  WITH SELECTIVE PHARMA STOCKS  WITH  MEDIUM TERM/LONG TERM  PROSPECTIVE.

1. MY  PRIME PICK  IS  ASTRAZEN PHARMA BUY@2500-2525  LEVEL  TGT 4400-4500

2.DIVISLAB  BUY@1650-1675  LEVEL  TGT  2000-2100

3. IPCA LAB   BUY@950-1050  LEVEL  TGT  1500-1600

4 .JBCHEMPHARMA   BUY@380-385  LEVEL  TGT 550-575

Sunday, November 24, 2019

CSB
                                                     CSB BANK-IPO

POSITIVE  SIDE:

CSB Bank provides products and services primarily through an extensive physical network of branches and ATMs. It operates in 16 States and four Union Territories in India, reaching 1.3 million customers through 414 branches (excluding three service branches and two asset recovery branches) and 277 ATMs, as on March 31, 2019.

STRONG  SME  CONTRIBUTION

In total loans SME customers accounted for 43%, 37%, and 32% as on March 31, 2017, March 31, 2018, and March 31, 2019, respectively.

STRONG  GOLD  LOAN PORTFOLIO
Gold loans constituted a major portion of advances, contributing 24%, 26%, and 31% of total advances as on March 31, 2017, March 31, 2018, and March 31, 2019, respectively.

RISK(NEGATIVE SIDE).

GROSS  NPA

  Gross NPAs represented 7.25%, 7.89%, and 4.87% of total advances as on March 31, 2017, March 31, 2018, and March 31, 2019, respectively.

BANK CONCNTRATING  BUSINESS ONLY  IN  SOUTH  INDIA.

Any adverse change in the economic, political, or geographical conditions of Kerala and other states in southern India can impact results of operations. Additionally.

MORE  CONCENTRATION  ON  GOLD  LOAN

 MAJOR BUSINESS  COMES  FROM GOLD LOAN, IF  GOLD  PRICE  WILL EFFECT ADVERSELY  BUSINESS WILL  BE  IN  RISK.


                                                      VALUEATION

WITH A  INTEREST  INCOME OF  732.3  CRORE ,  CSB  REPORTED A NET PROFIT  OF  44.27(LAST  2  YEARS  REPORTED  LOSS)  CORE AND  A EPS OF  3.86 .
CURRENTLY   CSB BANK’S  LOWER PRICE  BAND IS AROUND  50 PE X  ,2.2 X P/BV   WHICH IS  HIGHER TO PEER BANKS LIKE  FEDERAL  BANK  AND DCB.

PEER  VALUATION

FEDERAL  BANK (CMP 88)    11.19  PE , 1.27 X P/BV.

DCB                      (CMP 176)   15.4 PE ,  1.82X P/BV     .

KTKBANK             (CMP 74)      4.29 PE , .38 X P/BV

                       VALUATION PART    CSB  IS  EXPENCIVE   THAN  PEER  GROUP.

Disclaimer: This Blog, its owner, creator / contributor is not a research analyst and expressing opinion only as an individual investor in Indian equities. He/She is not responsible for any loss arising out of any information, post or opinion appearing on this blog. Investors are advised to consult financial consultant before acting on any such information. All information in this blog is posted for personal study.

* Can expect listing  gain  dont hold or fresh  buy not entertain .expecting below 200 level after listing  .

Friday, November 15, 2019




TINPLATE LTD  A SUBSIDIARY  OF  TATASTEEL ENGAGED  WITH  NON FERROUS

METAL SECTOR.  IT  IS  A  SMALL CAP  COMPANY

MKT  CAP-1454 CR

PE-22.5

DIVIDEND YIELD -1.47%,FV -10,

IT  IS A DEBT FREE COMPANY  WITH HIGH CASH RICH  RESERVE.

MOST  ATTRACTION  IS  MARKETCAP TO  SALES IT  COMES  AROUND .56

CMP@136   IAM EXPECTING A  TGT  OF  250.

Tuesday, November 5, 2019



GUJRATGAS LTD.

ENGAGED  IN THE  BUSINESS OF  GAS  DISTRIBUTION.IT IS  A  MULTI YEAR BREAKOUT ON THE CHART

1.  SALES  INCREASED 5093 CR TO 7754 CR.  DURING 2017-2019

2.  NET PROFIT INCREASED FROM 220 CR TO 417 CR. DURING 2017-2019

3.DEBT EQUITY  RATION  JUST .96

4. MARKET CAP TO SALES IS AROUND 1.75 

                              BUY  AROUND 190-195  FOR  A  TARGET  OF 400 KEEP  SL  AS  138 AS  CLOSING  BASE .